CD274 and neoplasm: Next, we aimed to determine whether combining therapy with anti-CD47, anti-PD-L1, and immunological death inducer chemotherapeutic agents (OXP or FOLFOX) could generate anti-tumor response compared to chemotherapy or bicombinig therapy with chemotherapy and checkpoint blockers.